TABLE 1.
Adverse Drug Events and Reasons for MC Discontinuation
| Participants, No. (%) | |||
|---|---|---|---|
| Mild severity | Moderate severity | Total | |
| Adverse drug events | |||
| Fatigue | 14 (10) | 1 (1) | 15 (11) |
| Dizziness | 2 (1) | 0 | 2 (1) |
| Euphoria or cognitive impairment | 5 (4) | 1 (1) | 6 (4) |
| Unpleasant taste | 3 (2) | 0 | 3 (2) |
| Increased appetite | 2 (1) | 0 | 2 (1) |
| Stomach upset | 2 (1) | 0 | 2 (1) |
| Throat discomfort | 1 (1) | 1 (1) | 2 (1) |
| Cough | 1 (1) | 0 | 1 (1) |
| Muscle spasms | 1 (1) | 0 | 1 (1) |
| Anxiety | 0 | 1 (1) | 1 (1) |
| “Burning” sensation on tongue/lips | 1 (1) | 0 | 1 (1) |
| Dry mouth | 1 (1) | 0 | 1 (1) |
| Experienced any adverse drug event | 31 (22) | 4 (3) | 34 (24) |
| Reason for MC discontinuation (n = 130)a | |||
| Lost to follow-up | 35 (27) | ||
| Cost | 14 (11) | ||
| Lack of efficacy | 8 (6) | ||
| Adverse events | 4 (3) | ||
| Unknown | 1 (1) | ||
| Subtotal | 62 (48) | ||
MC, medical cannabis.
a
Patients (n = 11) who were in treatment as of the end of the study period (October 31, 2018) but had not yet completed 4 follow-up visits were removed from this analysis.